Literature DB >> 24251542

Transient increase of interferon-stimulated genes and no clinical benefit by chloroquine treatment during acute simian immunodeficiency virus infection of macaques.

Monica Vaccari1, Claudio Fenizia, Zhong-Min Ma, Anna Hryniewicz, Adriano Boasso, Melvin N Doster, Christopher J Miller, Niklas Lindegardh, Joel Tarning, Alan L Landay, Gene M Shearer, Genoveffa Franchini.   

Abstract

Simian immunodeficiency virus (SIV) infection leads to AIDS in experimentally infected Rhesus macaques similarly to HIV-infected humans. In contrast, SIV infection of natural hosts is characterized by a down-regulation of innate acute responses to the virus within a few weeks of infection and results in limited pathology. Chloroquine (CQ) has been used in the treatment or prevention of malaria and has recently been shown to cause a decrease of immune activation and CD4 cell loss in HIV-infected individuals treated with antiretroviral therapy. Here, we treated Rhesus macaques with CQ during the acute phase of SIVmac251 infection with the intent to decrease viral-induced immune activation and possibly limit disease progression. Contrary to what was expected, CQ treatment resulted in a temporary increased expression of interferon (IFN)-stimulating genes and it worsened the recovery of CD4(+) T cells in the blood. Our findings confirm recent results observed in asymptomatic HIV-infected patients and suggest that CQ does not provide an obvious benefit in the absence of antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24251542      PMCID: PMC3976588          DOI: 10.1089/AID.2013.0218

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  52 in total

Review 1.  Antimalarial agents and lupus.

Authors:  D J Wallace
Journal:  Rheum Dis Clin North Am       Date:  1994-02       Impact factor: 2.670

2.  Inhibition of human immunodeficiency virus infectivity by chloroquine.

Authors:  W P Tsai; P L Nara; H F Kung; S Oroszlan
Journal:  AIDS Res Hum Retroviruses       Date:  1990-04       Impact factor: 2.205

3.  Chloroquine retinopathy in the rhesus monkey.

Authors:  A R Rosenthal; H Kolb; D Bergsma; D Huxsoll; J L Hopkins
Journal:  Invest Ophthalmol Vis Sci       Date:  1978-12       Impact factor: 4.799

4.  Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia.

Authors:  Guido Silvestri; Donald L Sodora; Richard A Koup; Mirko Paiardini; Shawn P O'Neil; Harold M McClure; Silvija I Staprans; Mark B Feinberg
Journal:  Immunity       Date:  2003-03       Impact factor: 31.745

5.  Mechanism of action of hydroxychloroquine as an antirheumatic drug.

Authors:  R I Fox
Journal:  Semin Arthritis Rheum       Date:  1993-10       Impact factor: 5.532

6.  Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release.

Authors:  Zhou Hong; Zheng Jiang; Wang Liangxi; Ding Guofu; Luo Ping; Lu Yongling; Pan Wendong; Wang Minghai
Journal:  Int Immunopharmacol       Date:  2004-02       Impact factor: 4.932

7.  Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner.

Authors:  Mark Rutz; Jochen Metzger; Tanja Gellert; Peter Luppa; Grayson B Lipford; Hermann Wagner; Stefan Bauer
Journal:  Eur J Immunol       Date:  2004-09       Impact factor: 5.532

8.  Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes.

Authors:  K Sperber; T H Kalb; V J Stecher; R Banerjee; L Mayer
Journal:  AIDS Res Hum Retroviruses       Date:  1993-01       Impact factor: 2.205

Review 9.  Acquired immunodeficiency syndrome--a review and update. History, characteristics of human immunodeficiency virus infection, its replication, biologic factors, and pathogenicity.

Authors:  N W Fox; C P McArthur
Journal:  Arch Fam Med       Date:  1993-10

10.  Steady-state pharmacokinetics of hydroxychloroquine in rheumatoid arthritis patients.

Authors:  D R Miller; S K Khalil; G A Nygard
Journal:  DICP       Date:  1991-12
View more
  8 in total

Review 1.  Type I interferon: understanding its role in HIV pathogenesis and therapy.

Authors:  Steven E Bosinger; Netanya S Utay
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

2.  HIV-1 Env Glycoprotein Phenotype along with Immune Activation Determines CD4 T Cell Loss in HIV Patients.

Authors:  Anjali Joshi; Melina Sedano; Bethany Beauchamp; Erin B Punke; Zuber D Mulla; Armando Meza; Ogechika K Alozie; Debabrata Mukherjee; Himanshu Garg
Journal:  J Immunol       Date:  2016-01-13       Impact factor: 5.422

3.  Plasmacytoid dendritic cells suppress HIV-1 replication but contribute to HIV-1 induced immunopathogenesis in humanized mice.

Authors:  Guangming Li; Menglan Cheng; Jun-Ichi Nunoya; Liang Cheng; Haitao Guo; Haisheng Yu; Yong-Jun Liu; Lishan Su; Liguo Zhang
Journal:  PLoS Pathog       Date:  2014-07-31       Impact factor: 6.823

Review 4.  Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS.

Authors:  Andrea Savarino; Iart Luca Shytaj
Journal:  Retrovirology       Date:  2015-06-18       Impact factor: 4.602

Review 5.  Interferon-alpha, immune activation and immune dysfunction in treated HIV infection.

Authors:  Lilian Cha; Cassandra M Berry; David Nolan; Allison Castley; Sonia Fernandez; Martyn A French
Journal:  Clin Transl Immunology       Date:  2014-02-28

Review 6.  The Significance of Type-I Interferons in the Pathogenesis and Therapy of Human Immunodeficiency Virus 1 Infection.

Authors:  Bowen Wang; Wen Kang; Jiahui Zuo; Wenzhen Kang; Yongtao Sun
Journal:  Front Immunol       Date:  2017-11-01       Impact factor: 7.561

Review 7.  Elucidating the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Chloroquine and Hydroxychloroquine.

Authors:  Seidu A Richard; Sylvanus Kampo; Maite Esquijarosa Hechavarria; Marian Sackey; Alexis D B Buunaaim; Eugene Dogkotenge Kuugbee; Thomas Winsum Anabah
Journal:  J Immunol Res       Date:  2020-09-25       Impact factor: 4.818

8.  The Modulation of Cholesterol Metabolism Is Involved in the Antiviral Effect of Nitazoxanide.

Authors:  Claudio Fenizia; Salomè Valentina Ibba; Claudia Vanetti; Sergio Strizzi; Jean-François Rossignol; Mara Biasin; Daria Trabattoni; Mario Clerici
Journal:  Infect Dis Rep       Date:  2021-07-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.